Earnings FlashALGN
Align Technology, Inc. (ALGN) gains despite earnings misses
Align Technology, Inc. (ALGN) gains 1.5% even after earnings misses, as investors weigh the latest results against the stock’s recent momentum.
Apr 29, 20262 MIN
TickerSpark Feed
healthcare
Everything tagged "healthcare" across research, earnings, and macro.
70 articles
Earnings AnalysisGEHC
GE HealthCare Technologies Inc. (GEHC) falls on deep earnings analysis
GE HealthCare Technologies Inc. (GEHC) falls after a closer look at earnings shows a profit miss, margin pressure, and a lowered full-year outlook despite solid revenue and backlog growth. This deep-dive analysis breaks down segment performance, inflation headwinds, and why investors focused on guidance rather than sales.
Apr 29, 202610 MIN
Research ReportREGN
Regeneron Pharmaceuticals (REGN): Dupixent Growth Offsets EYLEA Pressure
Regeneron combines a durable cash engine with a broad pipeline, while Dupixent growth and EYLEA HD adoption help offset legacy EYLEA biosimilar pressure. The stock screens as a Buy with valuation still reasonable for a mature biotech compounder.
Apr 29, 202623 MIN
Research ReportGEHC
GE HealthCare (GEHC): Backlog and PDx Growth vs. Margin Pressure
GE HealthCare offers a balanced medtech setup with a $21.8B backlog, growing pharmaceutical diagnostics, and solid free cash flow, but tariffs and margin pressure are still weighing on results.
Apr 29, 202624 MIN
Earnings FlashGEHC
GE HealthCare Technologies Inc. (GEHC) falls on earnings miss
GE HealthCare Technologies Inc. (GEHC) falls 13.8% after reporting an earnings miss, as investors react to weaker-than-expected results and pressure on the stock.
Apr 29, 20262 MIN
Research ReportGSK
GSK (GSK): Specialty Medicines Drive a Re-Rating
GSK is evolving from a mature pharma cash generator into a more balanced growth story, with Specialty Medicines driving faster growth and margins improving. The stock still looks reasonably valued versus its earnings power and pipeline.
Apr 29, 202621 MIN
Research ReportCNC
Centene (CNC): Medicaid Margin Recovery Is Gaining Traction
Centene just delivered a strong Q1 2026 beat-and-raise, with improving Medicaid and Medicare margins supporting a recovery thesis. The stock still looks inexpensive versus its earnings power, but execution on medical cost trend remains the key risk.
Apr 28, 202621 MIN
Research ReportHCA
HCA Healthcare (HCA): Scale, Cash Flow, and Policy Risk
HCA remains a high-quality hospital operator with steady volume growth, improving margins, and aggressive buybacks. Policy headwinds could pressure 2026 earnings, but the business still looks attractive for moderate-risk investors.
Apr 24, 202626 MIN
Research ReportTMO
Thermo Fisher Scientific (TMO): Quality Franchise, Price Debate
Thermo Fisher Scientific remains a top-tier life sciences platform with recurring revenue, strong cash flow, and multiple growth catalysts. The stock is a Buy, but the report argues the main question is valuation rather than business quality.
Apr 23, 202628 MIN
Earnings FlashTMO
Thermo Fisher Scientific Inc. (TMO) slips as earnings meets
Thermo Fisher Scientific Inc. (TMO) slips 2.0% after reporting earnings that met expectations, as investors react to the latest quarterly results.
Apr 23, 20262 MIN
Earnings AnalysisELV
Elevance Health Inc. (ELV) gains on deep earnings beat
Elevance Health Inc. (ELV) gained after a solid earnings beat and higher full-year guidance, but the deeper story is in the details: Medicare Advantage improved, Medicaid pressure persisted, and nonrecurring investment income boosted results. Here’s a full breakdown of what drove the quarter and what still matters.
Apr 23, 202612 MIN
Research ReportMEDP
Medpace Holdings (MEDP): Growth Is Strong, Valuation Isn’t Cheap
Medpace is delivering fast revenue growth, strong backlog, and net cash, but the stock already prices in a lot of good news. The report leans constructive, with a selective Buy on pullbacks rather than an aggressive chase.
Apr 22, 202627 MIN
On-Demand Research
Need research on a stock not covered here?
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the Generator